Skip to main content

Table 4 Univariate and multivariate analyses of clinical variables on intracranial progression -free survival

From: Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis

  Univariate
HR (95% CI)
P Multivariate
HR (95% CI)
P
Age (≥60/< 60) 1.66 (0.78–3.54) 0.17   
Gender (Female/Male) 0.64 (0.31–1.31) 0.204   
Smoking status (Smoking/Never) 1.41 (0.65–3.06) 0.375   
KPS (≥80/< 80) 0.34 (0.15–0.78) 0.006 0.34 (0.15–0.78) 0.011
EGFR mutation (exon 19 deletion/exon 21 L858R) 0.77 (0.39–1.52) 0.43   
Co-existing BMs (yes/no) 0.89 (0.34–2.33) 0.804   
Intracranial symptoms (yes/no) 1.40 (0.61–3.22) 0.413   
LM at the time of NSCLC diagnosis (yes/no) 0.60 (0.21–1.72) 0.324   
Treatment for LM
 WBRT (yes/no) 0.51 (0.25–1.04) 0.052   
 EGFR-TKIs (yes/no) 0.45 (0.22–0.91) 0.019 0.442 (0.22–0.91) 0.027
 WBRT+EGFR-TKIs/EGFR-TKIs alone 0.67 (0.27–1.67) 0.379   
  1. LM Leptomeningeal metastasis, KPS Karnofsky performance status, NSCLC Non-small-cell lung cancer, EGFR Epidermal growth factor receptor, TKI Tyrosine kinase inhibitor, WBRT Whole brain radiotherapy, ChT Chemotherapy, BMs Brain metastases